Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks
Summary
Congo will receive 70,000 doses of the Ervebo Ebola vaccine to help fight the current fast-spreading Ebola outbreak in eastern Congo. The vaccine has worked against other Ebola viruses before, but its effect on this specific virus type is still being studied.Key Facts
- Congo is getting 70,000 doses of the Ervebo vaccine, which is approved for Ebola virus but not specifically for the Bundibugyo virus causing the current outbreak.
- Early tests suggest Ervebo might offer some protection against the Bundibugyo virus.
- 20,000 doses are for a Phase 3 clinical trial to test the vaccine’s effectiveness on this virus.
- 50,000 doses will be used to vaccinate frontline and health workers.
- The current Ebola outbreak in Congo has infected 5,208 people and caused 2,476 deaths.
- This outbreak is spreading about three times faster than the 2014-2016 West Africa Ebola outbreak.
- There are no approved vaccines or treatments yet for the Bundibugyo virus.
- Many new cases are occurring outside of monitored groups, which makes tracking and controlling the outbreak harder.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
